Luisa M Stamm Selected Research

velpatasvir

3/2019	Sofosbuvir-velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India.
1/2019	Sofosbuvir/velpatasvir for patients with chronic genotype 3 HCV infection with compensated cirrhosis: Response to EASL Recommendations on Treatment of Hepatitis C 2018.
1/2019	Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir-containing regimen: Results from a retreatment study.
1/2019	Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.
1/2019	Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial.
10/2018	Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.
7/2018	Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals.
1/2018	Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients.
1/2017	Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
1/2017	Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Luisa M Stamm Research Topics

Disease

22	Infections 11/2022 - 10/2015
14	Fibrosis (Cirrhosis) 11/2022 - 08/2015
9	Chronic Hepatitis C 03/2019 - 11/2016
3	Hepatitis C 01/2019 - 10/2015
2	Headache (Headaches) 10/2018 - 01/2017
2	Fatigue 01/2017 - 01/2017
2	Nausea 01/2017 - 01/2017
2	Diarrhea 01/2017 - 01/2017
1	Chronic Hepatitis B 11/2022
1	Viremia 01/2022
1	Esophageal and Gastric Varices (Esophageal Varices) 01/2019
1	Hemorrhage 01/2019
1	Hepatocellular Carcinoma (Hepatoma) 01/2019
1	Virus Diseases (Viral Diseases) 01/2019
1	Sepsis (Septicemia) 01/2019
1	Liver Diseases (Liver Disease) 01/2019
1	Asthenia 10/2018
1	Sleep Initiation and Maintenance Disorders (Insomnia) 10/2018
1	Anemia 01/2017
1	Bronchitis 01/2017
1	Gastroenteritis 01/2017
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2016
1	Persistent Infection 01/2015

Drug/Important Bio-Agent (IBA)

16	SofosbuvirIBA 03/2019 - 10/2015
13	velpatasvirIBA 03/2019 - 01/2016
10	Ribavirin (Virazole)FDA LinkGeneric 01/2019 - 10/2015
5	sofosbuvir velpatasvir voxilaprevir drug combinationIBA 01/2019 - 01/2017
5	Antiviral Agents (Antivirals)IBA 07/2018 - 01/2016
5	voxilaprevirIBA 01/2017 - 01/2016
4	TabletsIBA 01/2019 - 01/2017
3	Protease Inhibitors (Protease Inhibitor)IBA 01/2017 - 01/2016
3	NucleotidesIBA 01/2017 - 11/2016
2	DNA (Deoxyribonucleic Acid)IBA 11/2022 - 01/2022
2	InterferonsIBA 01/2016 - 01/2016
1	entecavir FDA Link 11/2022
1	Reverse Transcriptase InhibitorsIBA 11/2022
1	Hepatitis B e AntigensIBA 11/2022
1	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 01/2019
1	Pharmaceutical PreparationsIBA 01/2018
1	Immunosuppressive Agents (Immunosuppressants)IBA 01/2018
1	efavirenz (Sustiva)FDA Link 01/2018
1	ledipasvirIBA 01/2017
1	Proteins (Proteins, Gene)FDA Link 01/2017
1	VimentinIBA 03/2016
1	Drug CombinationsIBA 01/2016
1	sofosbuvir drug combination ledipasvirIBA 01/2016
1	lathosterolIBA 01/2016
1	ChemokinesIBA 10/2015
1	Alanine Transaminase (SGPT)IBA 10/2015
1	CytokinesIBA 10/2015
1	Interleukin-18 (Interleukin 18)IBA 10/2015
1	RNA (Ribonucleic Acid)IBA 01/2015

Therapy/Procedure

5	Therapeutics 01/2019 - 08/2015
2	Aftercare (After-Treatment) 10/2018 - 01/2018
2	Duration of Therapy 11/2016 - 01/2016
1	Retreatment 01/2019
1	Liver Transplantation 01/2018